Labiotech.eu

Philips consortium cancer angle stilla 1

News and Trends 23 Nov 2017

The EU Gives €6.3M Grant to Anti-Cancer Consortium

The consortium of companies will use the EU’s money to support the development of personalized therapies for breast and rectal cancers. Horizon 2020 is the biggest ever EU Research and Innovation program with almost €80B made available to take exciting science to the market. The initiative has awarded a €6.3M grant to a group of companies brought […]

November 23, 2017 - 2 minutesmins - By Alex Dale

psoriasis treatment approval morphosys 1

News and Trends 23 Nov 2017

Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe

Following its FDA approval in July, MorphoSys’ anti-IL23 antibody has been approved to treat moderate-to-severe psoriasis by the European Commission. German biotech, MorphoSys, is a leader in the field of therapeutic antibodies for series diseases including cancer, arthritis and Alzheimer’s. Today, the company has announced that the licensee, Janssen, has received approval from the European Commission […]

November 23, 2017 - 3 minutesmins - By Alex Dale

Inside Labiotech 23 Nov 2017

Labiotech’s Identity Gets a Makeover

You may have noticed Labiotech has been changing it up a bit, adding a splash of paint and a curvy line here or there. Well, we decided it’s high time we improved our graphic identity. Alfredo has been the mastermind behind these new changes. He has recently joined us from Italy and has been doing […]

November 23, 2017 - 2 minutesmins - By Katherine Douglas

In Depth 23 Nov 2017

The Future is (Syn)Bio: How and when do we get there?

Last week, Philip and I attended a meeting with some of the pioneers and leaders of the synthetic biology field. They believe biology will be everywhere in the future, but how do we get ready for it? Digital technologies are now present in almost all aspects of our lives. It seems obvious today that companies […]

November 23, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2017

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a range of indications. It partnered up with the global pharma company, AbbVie, back in 2013, to develop a number of cystic fibrosis (CF) candidates for a […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells

Scientists at Cardiff University have used CRISPR/Cas9 genome editing technology to produce highly specific killer T cell receptors. Researchers at Cardiff University have replaced the regular receptors found on T cells with their own, which are geared up to better tracking down and killing cancer cells. The research reported in Blood explained how the group removed receptors that interact with immune cells […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […]

November 22, 2017 - 3 minutesmins - By Alex Dale

News and Trends 22 Nov 2017

Streamlining Vaccine R&D with Labflow Automation

In recent years, awareness for the automation of laboratory workflows has increased dramatically. As a result, researchers have worked tirelessly to make the improvement of lab digitalization and sensor technologies a main priority. Being able to collect large quantities of data from R&D and Quality Control (QC) in a short amount of time, has the […]

November 22, 2017 - 5 minutesmins - By External Contributor

Infographics 22 Nov 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of therapies based on RNA interference is on the brink of making it to the market. A technology that was awarded the Nobel prize in 2006, […]

November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

Can this French Biotech Make it Easier to Rescue People from Hypoglycemia?

Adocia’s ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk and Eli Lilly in rescuing severe hypoglycemia. Based in Lyon, France, Adocia develops new formulations to improve the performance of diabetes drugs, including an ultra-rapid insulin to help type 1 diabetics control their blood glucose levels […]

November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […]

November 21, 2017 - 1 minutemin - By Alex Dale

News and Trends 21 Nov 2017

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Step Pharma will use the proceeds of its first fundraising round to support the development of immunomodulators for autoimmune diseases towards the clinic. Step Pharma develops inhibitors targeting an enzyme called cytidine nucleotide triphosphate (CTPS1) for the treatment of a range of autoimmune diseases. The company is working on several candidates, the most advanced of which […]

November 21, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The EU Gives €6.3M Grant to Anti-Cancer Consortium

Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe

Labiotech’s Identity Gets a Makeover

The Future is (Syn)Bio: How and when do we get there?

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Streamlining Vaccine R&D with Labflow Automation

Infographic: What is RNAi Therapy? Targeting the Untargetable

Can this French Biotech Make it Easier to Rescue People from Hypoglycemia?

German Biotech Reels in €34M for its Cancer-Killing Technology

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!